Publications
64
Citations
1,516
Est. group size
~14
Recurring co-author estimate
Active years
20
Publishing since 2006
Lara Rizzotto's research focuses on cancer biology, particularly how tumor cells adapt their metabolism and stress responses to survive treatment, with work spanning ovarian cancer, melanoma, penile cancer, and chronic lymphocytic leukemia. Her studies examine mechanisms like drug resistance, RNA modifications, and cellular stress pathways to identify new vulnerabilities that could be targeted with existing or novel drugs. This work often combines laboratory models (such as patient-derived xenografts) with molecular analysis to understand why some cancers resist chemotherapy.
Publication output has been variable but shows an increase in recent years, rising from about 2 papers per year in 2020-2023 to 5 papers per year in 2024-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancers
Nature Communications · 2022
- 2022-RA-953-ESGO Serine metabolism remodeling after platinum-based chemotherapy is a new vulnerability in resistant ovarian cancer patients
Ovarian cancer · 2022
- Downregulation of the FTO m6A RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors
Nature Cancer · 2021
- Activation of the integrated stress response confers vulnerability to mitoribosome-targeting antibiotics in melanoma
The Journal of Experimental Medicine · 2021
- Establishment, Characterization, and Imaging of a First Platinum-resistant Penile Cancer Patient-derived Xenograft in Nude Mice: A eUROGEN Project
European Urology · 2020
- Establishment, characterization and imaging of a first platinum-resistant penile cancer patient derived xenograft in nude mice: An eUROGEN project
European Urology Open Science · 2020
- Activation of the Integrated Stress Response in drug-tolerant melanoma cells confers vulnerability to mitoribosome-targeting antibiotics
bioRxiv (Cold Spring Harbor Laboratory) · 2020
- Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide
Leukemia & lymphoma/Leukemia and lymphoma · 2017
- Cancer Research×4
- Blood×3
- bioRxiv (Cold Spring Harbor Laboratory)×3
- Proceedings of the National Academy of Sciences×2
- Journal of Experimental & Clinical Cancer Research×2
- Shanmugapriya Thangavadivel
Medicine · The Ohio State University
- Adam S. Kittai
Medicine · The Ohio State University
- Cecelia Miller
Medicine · The Ohio State University
- Amy S. Ruppert
Medicine · The Ohio State University
- Farrukh T. Awan
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile